Thu Dec 26 06:52:23 UTC 2024: ## Senores Pharmaceuticals IPO Overwhelmingly Subscribed, Allotment Status Due Thursday

**MUMBAI, INDIA** – Senores Pharmaceuticals Ltd.’s initial public offering (IPO) closed with a resounding success, exceeding expectations with a 93.41 times oversubscription. The ₹582.11 crore IPO, which concluded on December 24th, saw bids for over 79.72 crore shares against the 85.34 lakh shares on offer. All categories were significantly oversubscribed, with retail investors showing 89.21 times oversubscription, non-institutional investors at 96.11 times, and qualified institutional buyers at 94.66 times. Employee bids alone were nearly 20 times the allocated shares.

The IPO, comprised of a fresh issue of ₹500 crore and an offer for sale (OFS) of ₹82.11 crore, will see allotment status finalized on December 26th. Investors can check their allotment status on the websites of the BSE, NSE, and registrar Link Intime India Pvt Ltd. Refunds and share transfers to Demat accounts are scheduled for December 27th, with shares slated to list on the NSE and BSE on December 30th.

Senores Pharmaceuticals plans to use the IPO proceeds to establish a sterile injection manufacturing facility in Atlanta and to address working capital needs. The company manufactures a diverse range of specialty pharmaceuticals across various therapeutic segments. As of March 2024, it operated three R&D facilities in India and the US.

Read More